表紙
市場調査レポート

EpiCast Report:多発性硬化症の疫学予測

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 258690
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
EpiCast Report:多発性硬化症の疫学予測 EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2024
出版日: 2015年09月14日 ページ情報: 英文 58 Pages
概要

多発性硬化症(MS)は世界で毎年250万人に影響を与えており、ヤングアダルトにおいては最大の衰弱性神経疾患です。調査対象10ヶ国全体の症例数は 2014年に909,398件と推計され、2024年までに 942,567件に増加すると予測されています。

当レポートでは、多発性硬化症(MS)のリスク因子および世界的動向について調査し、主要8市場(米国、フランス、ドイツ、イタリア、スペイン、英国、日本、カナダ)および新興市場(インド・中国)のデータを提供しております。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク因子と共存症
    • MS患者の家族はMSを発症する1%〜5%のリスクを持つ
    • 女性はMSを発症するリスクが2倍、しかし男性は予後が悪い
    • コーケイジャン(Caucasian)はその他の人種/民族よりもMSリスクが高い
    • MSに対するビタミンDの予防効果は、生まれた地域・月と関連する可能性がある
    • 環境暴露のタイミングがMSリスクに影響を与える
    • 受動喫煙はMSリスクを増加させ、予後を悪化させる可能性がある
    • 自己免疫疾患はMSの共存症となる可能性
    • 精神性共存症はMS患者の最大60%に見られ、再発率に影響を与える可能性がある
  • 世界の動向
    • 北米
    • 欧州
    • アジア
  • 予測手法
    • 利用ソース
    • 利用しなかったソース
    • 予測の前提条件・手法
  • 多発性硬化症の疫学予測
    • 有病数
    • 有病数:年齢別
    • 有病数:性別
    • 発症数
    • 発症数:年齢別
    • 発症数:性別
    • 多発性硬化症のサブタイプ
  • 考察
    • 疫学動向の結論
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考資料
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER088-15

Multiple sclerosis (MS) is an inflammatory disease in which the myelin sheaths around the axons of the brain and spinal cord are damaged, leading to demyelination and a wide range of signs and symptoms. The course of MS seems to be unpredictable as some people diagnosed with the condition appear to be normal and healthy for a few years after diagnosis, while others may be debilitated very quickly after diagnosis. People with MS experience a host of symptoms, which may vary with the course of the disease. The estimated prevalence and incidence of MS vary greatly between countries, within countries, and by age and sex.

In 2014, there were a total of 909,398 diagnosed prevalent cases of MS in the 10MM, and GlobalData epidemiologists forecast that by 2024, the number of diagnosed prevalent cases of MS will grow to 942,567 cases. In 2014, there were a total of 60,535 diagnosed incident cases of MS in the 10MM, and GlobalData epidemiologists forecast the number of diagnosed incident cases of MS to grow to 62,635 cases in the 10MM in 2024.

GlobalData epidemiologists forecast the diagnosed prevalent and diagnosed incident cases of MS in the 10MM from 2014-2024 using country-specific studies published in peer-reviewed journals that provided the age- and sex-specific diagnosed prevalence and diagnosed incidence of MS in the respective markets. The epidemiologists made sure that all the selected nationally-representative studies in the respective countries assessed the prevalence and incidence using the same study definition, thereby ensuring that the results forecast for each country are comparable. The forecast methodology was consistent across all the 10MM to allow for a meaningful comparison among them.

Scope

  • The Multiple Sclerosis (MS) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for MS in the ten major markets (10MM) (US, France, Germany, Italy, Spain, UK, Japan, Canada, China, and India). It includes a 10-year epidemiological forecast of the diagnosed prevalent and diagnosed incident cases of MS segmented by sex and age in these markets. This report also includes a discussion of three types of MS; relapse remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS).
  • The MS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 10MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global MS market.
  • Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for MS therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
    • 3.2.1. Family members of MS patients have a 1-5% risk of developing MS
    • 3.2.2. Women are twice as likely to develop MS, but men have a worse prognosis
    • 3.2.3. Caucasians have a higher risk of MS than any other race/ethnicity
    • 3.2.4. Protective effect of vitamin D on MS may relate to latitude and month of birth
    • 3.2.5. Timing of environmental exposures affects MS risk
    • 3.2.6. Exposure to smoking may increase MS risk and worsen prognosis
    • 3.2.7. Autoimmune diseases are comorbidities of MS
    • 3.2.8. Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates
  • 3.3. Global Trends
    • 3.3.1. North America
    • 3.3.2. Europe
    • 3.3.3. Asia
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for MS (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of MS
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of MS
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of MS
    • 3.5.4. Diagnosed Incident Cases of MS
    • 3.5.5. Age-Specific Diagnosed Incident Cases of MS
    • 3.5.6. Sex-Specific Diagnosed Incident Cases of MS
    • 3.5.7. MS Subtypes
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidites for MS
  • Table 2: Sources of MS Diagnosed Prevalence and Diagnosed Incidence Data Used in the Epidemiology Forecast
  • Table 3: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 4: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 5: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N (Row %), 2014
  • Table 6: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Table 7: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N (Row %), 2014
  • Table 8: 10MM, Diagnosed Incident Cases of MS, by Sex, N (Row %), 2014

List of Figures

  • Figure 1: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 2: 10MM, Diagnosed Prevalent Cases of MS, by Age, Men and Women, N, 2014
  • Figure 3: 10MM, Diagnosed Prevalent Cases of MS, Ages ≥20 Years, by Sex, N, 2014
  • Figure 4: 10MM, Diagnosed Incident Cases of MS, Ages ≥20 Years, Men and Women, N, Select Years, 2014-2024
  • Figure 5: 10MM, Diagnosed Incident Cases of MS, by Age, Men and Women, N, 2014
  • Figure 6: 10MM, Diagnosed Incident Cases of MS, by Sex, N, 2014
  • Figure 7: 10MM, MS Subtype Distributions, %*, 2014
Back to Top